Fleroxacin combined with rifampin.
We determined the effect of the combination of rifampin and fleroxacin against Enterobacteriaceae and streptococcal species. None of the 65 isolates tested by checkerboard assay demonstrated synergy, 12% of isolates showed an additive effect; 86.7% were indifferent, and only 1 isolate showed antagonism. The mean FIC was 1.2. When using 2 and 8 micrograms/ml of rifampin, fleroxacin MICs of 285 isolates of Enterobacteriaceae, Pseudomonas aeruginosa, Haemophilus influenzae, staphylococci, streptococci, Bacteroides, and Clostridium were not increased, but synergy was not demonstrated. Time-kill studies against Escherichia coli, P. aeruginosa, Enterobacter cloacae, Staphylococcus aureus, and Enterococcus faecalis failed to show increased killing when the two agents were present at one-half the MBC. The fleroxacin-rifampin interaction is one of indifference but provides coverage for species not adequately inhibited by fleroxacin.
Zhang
Y X
YX
Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York.
Neu
H C
HC
D000150:Acinetobacter / Q000187:drug effects; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D004336:Drug Antagonism; D004357:Drug Synergism; D004755:Enterobacteriaceae / Q000187:drug effects; D016576:Fleroxacin; D006801:Humans; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012293:Rifampin / Q000494:pharmacology*; D013210:Staphylococcus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects
D000890:Anti-Infective Agents; D002939:Ciprofloxacin; D016576:Fleroxacin; D012293:Rifampin